

## **Product datasheet for TL318182**

## OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

## **TAB3 Human shRNA Plasmid Kit (Locus ID 257397)**

**Product data:** 

**Product Type:** shRNA Plasmids

**Product Name:** TAB3 Human shRNA Plasmid Kit (Locus ID 257397)

**Locus ID:** 257397

**Synonyms:** MAP3K7IP3; NAP1

Vector: pGFP-C-shLenti (TR30023)

E. coli Selection: Chloramphenicol (34 ug/ml)

Mammalian Cell

Selection:

Puromycin

Format: Lentiviral plasmids

**Components:** TAB3 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 257397).

5µg purified plasmid DNA per construct

29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.

RefSeq: NM 152787, NM 198312, NM 152787.1, NM 152787.2, NM 152787.3, NM 152787.4,

BC032526, BC032526.1, NM 152787.5

UniProt ID: O8N5C8

Summary: The product of this gene functions in the NF-kappaB signal transduction pathway. The

encoded protein, and the similar and functionally redundant protein MAP3K7IP2/TAB2, forms

a ternary complex with the protein kinase MAP3K7/TAK1 and either TRAF2 or TRAF6 in response to stimulation with the pro-inflammatory cytokines TNF or IL-1. Subsequent MAP3K7/TAK1 kinase activity triggers a signaling cascade leading to activation of the NF-

kappaB transcription factor. The human genome contains a related pseudogene.

Alternatively spliced transcript variants have been described, but their biological validity has

not been determined. [provided by RefSeq, Jul 2008]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.







## Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).